New drug cocktail targets Hard-to-Treat colorectal cancer mutation

NCT ID NCT06959589

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drug combinations for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. In one group, patients who haven't had treatment yet will receive the drugs IBI351 and cetuximab β plus chemotherapy (FOLFIRI). In another group, patients whose cancer got worse after first treatment will get just IBI351 and cetuximab β. The goal is to see if these combinations shrink tumors better than past treatments. About 50 adults aged 18-75 will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IBI351 and cetuximab β (with or without FOLFIRI chemotherapy)
What this could lead to
If successful, this could offer a new targeted treatment option for people with a specific genetic mutation (KRAS G12C) in advanced colorectal cancer, potentially improving tumor shrinkage rates.
What could go wrong
This is a small, early-phase (Phase II) study with only 50 participants, so results may not apply broadly. The combination may cause side effects, and the expected improvement in remission rates is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.